Alnylam Pharmaceuticals Q3 Earnings Conference Call - ALNYLAM PHARMACEUTICALS INC

Financial Performance:

• Q3 net product revenues reached $1.29 billion, a 52% year-over-year increase and 10% sequential growth.
• TTR franchise generated $1.15 billion in Q3 revenue (59% YoY growth), with U.S. TTR revenues rising 69% YoY and $100 million QoQ.
• Q3 growth drivers included an $81 million increase in demand, a $17 million inventory benefit, and a $10 million one-time gross-to-net adjustment; these one-time factors are expected to be headwinds in Q4.
• Collaboration revenue was $71 million (down 80% YoY), excluding a $300 million one-time milestone recognized in Q3 2025.
• Gross margin on product sales was 72%, a 5-point decrease YoY driven by higher royalties paid to Sanofi on Amvutra.
• Non-GAAP operating income was $425 million (down 11% YoY), while GAAP net income was $2.2 billion, significantly boosted by a $1.9 billion non-cash tax benefit from the release of valuation allowances.
• Cash, cash equivalents, and marketable securities totaled $3.6 billion at quarter-end.

Guidance and Future Outlook:

• Full-year 2026 TTR revenue guidance is reiterated at $4.2 billion to $4.5 billion; expected to land at the low end due to slower demand translation from field expansion and Q4 ordering caution.
• Management does not expect accelerated demand growth in Q4 2026 or material top-line contribution from field expansion in the 2026 forecast.
• 2027 product revenue guidance will be withheld until the Q4 2026/Full Year 2026 earnings call in February to allow time to assess the impact of the finalized CMS 340B rule.
• Nucreceran (ALN-TTR01) is on track for a 2030 launch, with the Triton CM study expansion not altering this timeline.
• Brazosaran pivotal study in Huntington's disease is planned to initiate in 2027.
• The company maintains its long-term ambition of achieving a 25%+ total revenue CAGR through 2030, targeting a 33% TRX market share in the U.S. ATTR market by 2030.

Business Segments and Product Lines:

• Amvutra (ATTR-CM): Q3 total category prescriptions grew ~40% YoY; Amvutra holds 24% of total TRX (Treatments per eXisting and new) and >30% of new-to-brand prescriptions (NBRX). Approximately 80% of prevalent patients remain untreated.
• Nucreceran (TTR Silencer): Enrollment in the Triton CM study expanded from 1,750 to 2,250 patients to ensure statistical power against lower-than-expected event rates in the evolving standard of care; study remains event-driven with all-cause mortality as the primary endpoint.
• Brazosaran (Huntington's Disease): Phase 1 interim data showed 60-64% reduction in CSF mutant HTT with no dose-dependent safety signals; moving toward a placebo-controlled pivotal trial in 2027.
• Pipeline Updates: Phase 1 data for ALN6400 (bleeding disorders) expected at ASH (Dec); Phase 2 HHT and Phase 1 obesity (ALN2232) data expected at Q4 call (Feb).

Market and Competitive Landscape:

• ATTR-CM market is growing robustly, but utilization deepens slowly as physicians gain experience; only ~1/3 of active prescribers have tried Amvutra.
• Competition includes TTR stabilizers and other RNAi therapies; Amvutra maintains a differentiated quarterly dosing profile and clinical outcome benefits.
• U.S. TTR market growth is driven by expanding prescriber base and community center adoption; international growth fueled by uptake in Japan and Germany despite price reductions in some markets.
• UnitedHealth implemented a more restrictive first-line Amvutra policy in Medicare Advantage effective Oct 1, creating potential delays for new patient starts but with exception processes available.

Risks and Challenges:

• 340B Rule: A proposed CMS rule change could reduce reimbursement for 340B drugs if finalized as proposed; effective Jan 1, 2027, potentially causing inventory ordering volatility in Q4 2026.
• Demand Acceleration: Management expressed dissatisfaction with the current pace of demand growth despite expanded sales force, citing the time required to change prescribing behaviors among new physicians.
• Clinical Trial Event Rates: Secular trends involving earlier diagnosis and background therapies (e.g., SGLT2 inhibitors) may lower cardiovascular event rates, requiring larger sample sizes to prove efficacy.
• Access Restrictions: Evolving payer policies and potential 340B economic shifts could create barriers to patient access or site-of-care changes.

Management Commentary and Tone:

• Tone was confident in the long-term value of the TTR franchise and pipeline but candid about near-term commercial execution challenges.
• Management acknowledged being "not yet satisfied" with the underlying demand growth rate and emphasized the need for a "laser-like focus" on converting prescriber engagement into patient starts.
• Strategic emphasis placed on the "trial begets preference" model, where early experience leads to higher utilization.
• Commitment to the "Alnylam 2030" vision remains firm, balancing immediate commercial execution with long-term R&D investments.

Analyst Questions and Answers:

• Triton CM Design: Management confirmed no changes to the therapeutic hypothesis or drug effect expectations; the 500-patient expansion is solely to account for lower event rates, not to fix a flawed study design.
• Demand Lag: Explained that new prescribers require frequent visits to overcome non-clinical barriers (billing, coordination, prior auth); once experienced, adoption deepens significantly.
• 340B Impact: No specific quantification provided, but management anticipates potential impacts on both net price (via discounts or WAC shifts) and volume; options include contracting with 340B entities or shifting patients to third-party infusion/home care.
• Pipeline Timing: Delays in HHT and obesity data reporting are due to the studies concluding near year-end; data will be released at the Q4 call.
• 2030 CAGR: Management reaffirmed the 25%+ CAGR guidance despite recent headwinds, citing the large untreated patient pool and ability to capture ~33% market share.

Other Key Points:

• Amvutra has secured access for ~99% of covered lives, with ~90% of patients living within 10 miles of a treatment site.
• The company has onboarded over 2,000 new unique prescribers since the Amvutra CM launch.
• Nucreceran's Triton PN study continues alongside the expanded CM study, maintaining the 2030 launch target for the TTR franchise.
• Management highlighted the importance of the HTT1A isoform target in Huntington's disease as a key differentiator of the Brazosaran program compared to competitors.